> Prestwick Pharmaceuticals has withdrawn its IPO due to market conditions. Report
> Genzyme has paid $12 million for gene therapy assets from Avigen. Report
> Oscient Pharmaceuticals has reached agreement with the FDA on two late-stage trials for Ramoplanin, an experimental treatment for bacterial disease. Release
> The FDA has issued an approval letter to Canada's Biovail for an orally disintegrating tablet formulation of citalopram hydrobromide (HBr) for the treatment of depression. Release
> A large study has found that using x-rays to search for lung cancer delivers a large number of false positives but also often finds the disease at an early stage. Report
> CollaGenex Pharmaceuticals of Newton, PA is selling $29 million of common stock. Release
> Oxonica of Mountain View, CA has acquired Nanoplex Technologies, which has been developing nanobased materials for the life sciences industry. Release
> The fledgling biotech systems-provider Nexus Biosystems has completed an unspecified first round of venture capital and opened office in Poway, CA. Nexus CEO John Lillig contributed venture capital to the round. Release
> Novartis has acquired the US OTC rights for Prevacid after it loses patent protection in 2009. Report
> Canada's Inflazyme is proceeding with a Phase IIb study of its oral, once a day, anti-inflammatory medication for the control of asthma. Release
> OXiGENE has completed a public offering of 7.4 million shares. Release
> Acusphere has cumulatively enrolled 700 patients in the pivotal Phase III clinical program for the cardiovascular drug AI-700, its lead product candidate. Release
> Critical Therapeutics has begun two pharmacokinetic studies of zileuton tablets. Release
And Finally… New research shows that silver, an ancient bacteria-fighter, can play a fresh role in fighting disease. Article